Autolus Therapeutics plc
AUTL· Nasdaq
AUTLAutolus Therapeutics plc
Source filing unavailable
| Metric | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|
| Revenue | — | $269.00K | $338.00K |
| Net Income | -$37.06M | -$33.27M | -$29.87M |
| EPS Diluted | -$0.41 | -$0.53 | -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
